Relay Therapeutics has raised $520m in venture capital since 2016, including a $400m Series C round announced on Dec. 20, without relaying a lot of information publicly about how it will translate its platform for interrogating proteins in motion into cancer drug candidates.
The Cambridge, Mass.-based company launched in Sept. 2016 with a $57m Series A round and plans to marry computational technology with insights in biology, biophysics and chemistry to build a platform for observing proteins in motion rather than as static images. Relay, which raised $63m in Series B cash a year ago, intends to understand how the conformation of proteins relates to function and develop drugs that modulate protein conformation
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?